Novogen drug acts on prostate cancer
Tuesday, 23 November, 2004
Novogen (ASX: NRT) subsidiary Marshall Edwards (LSE AIM: MSH, Nasdaq: MSHL) has reported that its lead drug phenoxodiol can slow down the progression of hormone refractory prostate cancer.
The results from a Phase Ib/IIa study of the drug in men with advanced metastatic disease were reported at the American Association of Cancer Research conference in Florida last week.
The dose response study showed that at the higher doses, the drug slowed the progression of disease and affected PSA levels over a period of 6-18 months, with no apparent toxicity, suggesting that the drug exerted an anti-tumour effect.
The company is planning a Phase IIb/IIIa multicentre international clinical trial to further test the drug in men with hormone refractory prostate cancer.
Personalised melanoma vaccine cuts risk of recurrence
Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
